

CLAIMS

1. ~~A method of treating~~Use of an antibody in the manufacture of a medicament for the treatment of an inflammatory disease in a subject in need thereof, ~~comprising administering to the subject an isolated antibody~~ wherein the antibody binds to the extracellular domain of human Tissue Factor (TF), wherein the antibody binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FVIIa.

~~2. The method of claim 1, wherein the viral infection is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~~

~~3.2.~~3.2. The ~~method use~~method use of claim 1, wherein the inflammatory disease is ~~selected from:~~

colitis, inflammatory bowel disease, arthritis, acute lung injury, acute respiratory distress syndrome (ARDS), and Respiratory Syncytial Virus (RSV);

a viral infection, optionally a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);

a cardiovascular disease or injury, optionally myocardial infarction; or

a cardiovascular disease associated with upregulation of protease-activated receptor 2 (PAR-2).

~~4. The method of claim 3, wherein the inflammatory disease is colitis.~~

~~5. The method of claim 3, wherein the inflammatory disease is inflammatory bowel disease (IBD).~~

~~6. The method of claim 3, wherein the inflammatory disease is arthritis.~~

~~7. The method of claim 3, wherein the inflammatory disease is acute lung injury.~~

~~8. The method of claim 3, wherein the inflammatory disease is ARDS.~~

~~9. The method of claim 3, wherein the inflammatory disease is RSV.~~

~~10. The method of claim 1, wherein the inflammatory disease is a cardiovascular disease or injury.~~

~~11. The method of claim 10, wherein the cardiac disease or injury is myocardial infarction.~~

~~12. The method of claim 1, wherein the inflammatory disease is a cardiovascular disease associated with upregulation of protease-activated receptor 2 (PAR-2).~~

3. The use of claim 1, wherein the inflammatory disease is a neurological disease, an inflammatory skin disease, rheumatism, vasculitis, lupus, dermatitis, or dermatosis due to acute inflammatory component.

4. The use of claim 1, wherein the inflammatory disease is an inflammatory disease that damages the skin or an inflammatory disease that damages the gastrointestinal tract.

13.5. The method of any one of claims 1-12 use of any one of claims 1 to 4, wherein:

(a) the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA); and/or-

14. The method of any one of claims 1-13, wherein (b) the isolated human antibody does not inhibit or inhibits human thrombin generation to a lesser extent, as determined by thrombin generation assay (TGA), compared to a reference antibody comprising a V_H sequence of SEQ ID NO:821 and a V_L sequence of SEQ ID NO:822;

15. The method of claim 14, optionally wherein binding between the isolated antibody and a variant TF extracellular domain comprising a mutation at amino acid residue 149 of the sequence shown in SEQ ID NO:810 is less than 50% of the binding between the isolated antibody and the extracellular domain of TF of the sequence shown in SEQ ID NO:810, as determined by the median fluorescence intensity value of the isolated antibody relative to an isotype control in a live cell staining assay; and/or-

The method of any one of claims 1 to 15, wherein (c) the antibody comprises

16. (i) all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from an antibody group in Table 35, wherein the all three heavy chain CDRs and the all three light chain CDRs are from the same antibody group; or-

17. The method of any one of the claims 1 to 15, wherein the antibody comprises (ii) all three heavy chain Complementary Determining Regions (CDRs) and all three light chain CDRs from an antibody in any one of Tables 15-34, wherein the all three heavy chain CDRs and the all three light chain CDRs are from the same antibody;

18. The method of claim 17, optionally comprising all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 25A, the

antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea; or:-

~~19. The method of claim 18, comprising all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~20. The method of claim 18, comprising all three heavy chain CDRs and all three light chain CDRs from: the antibody designated 25A, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~21. The method of any one of claims 1 to 15, wherein the antibody comprises (iii) a VH Domain sequence and VL domain sequence from Table 14, wherein the VH and VL domain sequences are from the same group in Table 14; or:-~~

~~22. The method of any one of claims 1 to 15, wherein the antibody comprises (iv) a VH Domain sequence and VL domain sequence from Table 13, wherein the VH and VL domain sequences are from the same clone in Table 13.~~

23.6. The ~~method use~~ of claim 1 or ~~135(a)~~, wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:797; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:798; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:799; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:800; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:801; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:802, optionally wherein:-

~~24. The method of claim 23, wherein~~ the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:571; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:572; a VH-CDR3 comprising the sequence set forth in SEQ ID

NO:573; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:574; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:575; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:576; or-

~~25. The method of claim 23, wherein~~ the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:609; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:610; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:611; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:612; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:613; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:614; or-

~~26. The method of any one of claims 1 to 13 and claim 23, wherein~~ the antibody comprises: a VH sequence comprising the sequence set forth in SEQ ID NO:769 and a VL sequence comprising the sequence set forth in SEQ ID NO:770, optionally-

~~27. The method of claim 26, wherein~~ the antibody comprises: (i) a VH sequence comprising the sequence set forth in SEQ ID NO:569 and a VL sequence comprising the sequence set forth in SEQ ID NO:570; -

~~28. The method of claim 26, wherein the antibody comprises: or (ii)~~ a VH sequence comprising the sequence set forth in SEQ ID NO:607 and a VL sequence comprising the sequence set forth in SEQ ID NO:608; or-

~~29. The method of claim 24 or 28, wherein~~ the antibody comprises: a heavy chain comprising the sequence set forth in SEQ ID NO:924 and a light chain comprising the sequence set forth in SEQ ID NO:925; or-

~~30. The method of claim 26, wherein~~ the antibody comprises: a VH sequence comprising the sequence set forth in SEQ ID NO:645 and a VL sequence comprising the sequence set forth in SEQ ID NO:646; or-

~~31. The method of claim 25 or 30, wherein~~ the antibody comprises: a heavy chain comprising the sequence set forth in SEQ ID NO:926 and a light chain comprising the sequence set forth in SEQ ID NO:927.

32.7. The ~~method use~~ of any one of claims 1 to 05(b), wherein:

the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:779; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:780; a VH-CDR3

comprising the sequence set forth in SEQ ID NO:781; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:782; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:783; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:784; or;

~~33. The method of any one of claims 1 to 16, wherein~~ the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:872; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:873; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:874; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:875; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:876; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:877; or;

~~34. The method of claim 33, optionally~~ wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:884; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:885; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:886; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:887; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:888; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:889; or;

~~35. The method of any one of claims 1 to 16 and 33, wherein~~ the antibody comprises: a VH sequence comprising the sequence set forth in SEQ ID NO:868 and a VL sequence comprising the sequence set forth in SEQ ID NO:869; optionally;

~~36. The method of claim 35, wherein the antibody comprises: (i)~~ a VH sequence comprising the sequence set forth in SEQ ID NO:189 and a VL sequence comprising the sequence set forth in SEQ ID NO:190; or;

~~37. The method of claim 35, wherein the antibody comprises: (ii)~~ a VH sequence comprising the sequence set forth in SEQ ID NO:836 and a VL sequence comprising the sequence set forth in SEQ ID NO:837; or;

~~38. The method of claim 34 or 37, wherein~~ the antibody comprises: a heavy chain comprising the sequence set forth in SEQ ID NO:920 and a light chain comprising the sequence set forth in SEQ ID NO:921.

39.8. The ~~method-use~~ of any one of claims 1 to ~~465(c)(i)~~, wherein:

the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:878; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:879; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:880; a VL-CDR1 comprising the sequence

set forth in SEQ ID NO:881; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:882; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:883, optionally.

~~40. The method of claim 39,~~ wherein the antibody comprises: a VH-CDR1 comprising the sequence set forth in SEQ ID NO:267; a VH-CDR2 comprising the sequence set forth in SEQ ID NO:268; a VH-CDR3 comprising the sequence set forth in SEQ ID NO:269; a VL-CDR1 comprising the sequence set forth in SEQ ID NO:270; a VL-CDR2 comprising the sequence set forth in SEQ ID NO:271; and a VL-CDR3 comprising the sequence set forth in SEQ ID NO:272; or.

~~41. The method of any one of claims 1 to 16 and 39, wherein~~ the antibody comprises: a VH sequence comprising the sequence set forth in SEQ ID NO:870 and a VL sequence comprising the sequence set forth in SEQ ID NO:871, optionally.

~~42. The method of claim 41,~~ wherein the antibody comprises: a VH sequence comprising the sequence set forth in SEQ ID NO:303 and a VL sequence comprising the sequence set forth in SEQ ID NO:304; or.

~~43. The method of claim 40 or 42, wherein~~ the antibody comprises: a heavy chain comprising the sequence set forth in SEQ ID NO:922 and a light chain comprising the sequence set forth in SEQ ID NO:923.

44.9. The ~~method of any one of the preceding claims~~ suse of any one of claims 1 to 8, wherein:

the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea; and/or.

~~45. The method of claim 44, wherein the antibody competes for binding to human TF with the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~46. The method of claim 44, wherein the antibody competes for binding to human TF with the antibody designated 25A, the antibody designated 25A5, the antibody designated 25A5-T,~~

~~the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

~~47. The method of any of the preceding claims, wherein _____~~ the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, the antibody designated 25G9, the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.

~~48. The method of claim 47, wherein the antibody binds to the same human TF epitope bound by the antibody designated 43B, the antibody designated 43B1, the antibody designated 43B7, the antibody designated 43D, the antibody designated 43D7, the antibody designated 43D8, the antibody designated 43E, or the antibody designated 43Ea.~~

~~49. The method of claim 47, wherein the antibody binds to the same human TF epitope bound by the antibody designated 25A, the antibody designated 25A5, the antibody designated 25A5-T, the antibody designated 25G, the antibody designated 25G1, or the antibody designated 25G9.~~

50-10. The ~~method~~ use of any one of ~~the preceding claims~~ claims 1 to 9, wherein the antibody does not inhibit human thrombin generation as determined by thrombin generation assay (TGA), does not reduce the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, does not increase the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, does not decrease the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, allows human thrombin generation as determined by thrombin generation assay (TGA), maintains the thrombin peak on a thrombin generation curve (Peak IIa) compared to an isotype control, maintains the time from the assay start to the thrombin peak on a thrombin generation curve (ttPeak) compared to an isotype control, preserves the endogenous thrombin potential (ETP) as determined by the area under a thrombin generation curve compared to an isotype control, binds human TF at a human TF binding site that is distinct from a human TF binding site bound by human FX, does not interfere with the ability of TF:FVIIa to convert FX into FXa, and does not compete for binding to human TF with FVIIa.

~~51.11.~~ The ~~method of any one of the preceding claims~~ use of any one of claims 1 to 10,
wherein:

the three heavy chain CDRs and the three light chain CDRs are determined using
exemplary, Kabat, Chothia, AbM, Contact, or IMGT numbering; ~~and/or-~~

~~52.~~ The ~~method of any of the preceding claims, wherein~~ _____ the antibody specifically
binds to cynomolgus TF; ~~and/or-~~

~~53.~~ The ~~method of any of the preceding claims, wherein~~ _____ the antibody binds to
specifically mouse TF; ~~and/or-~~

~~54.~~ The ~~method of any of the preceding claims, wherein the~~ the antibody binds to
specifically rabbit TF; ~~and/or-~~

~~55.~~ The ~~method of any of the preceding claims, wherein the~~ the antibody binds to
specifically pig TF; ~~and/or-~~

~~56.~~ The ~~method of any of the preceding claims, wherein the~~ the disease involves
vascular inflammation; ~~and/or-~~

~~57.~~ The ~~method of any one of the preceding claims wherein the~~ _____ the disease
involves local inflammation; ~~and/or-~~

~~58.~~ The ~~method of any one of the preceding claims wherein the~~ _____ the disease
involves systemic inflammation; ~~and/or-~~

~~59.~~ ~~The method of any one of the preceding claims, wherein~~ _____ the disease involves
infiltration of mononuclear cells and/or granulocytes, ~~optionally-~~

~~60.~~ ~~The method of claim 59, wherein the mononuclear cells comprise macrophages and/or~~
lymphocytes, ~~and/or-~~

~~61.~~ The ~~method of claim 59 or 60,~~ wherein the granulocytes comprise neutrophils and/or
eosinophils.

~~62.12.~~ The ~~method of any one of claims 1 and 13-61~~ use of any one of claims 1 to 11,
wherein:

(a) ~~the inflammatory disease is selected from the group consisting of: colitis,~~
~~inflammatory bowel disease, arthritis, acute lung injury, acute respiratory distress syndrome-~~

~~(ARDS), Respiratory Syncytial Virus (RSV), myocardial infarction, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~~

~~63. The method of any one of the preceding claims, the antibody is to be administered wherein upon administration~~ to a subject, and the antibody reduces the total leukocyte count, optionally.

~~64. The method of claim 63,~~ wherein the total leukocyte count is determined by light microscopy; and/or.

~~65. The method of any one of the preceding claims, wherein upon (b) the antibody is to be administered administration~~ to a subject and, the antibody reduces the total number of granulocytes, optionally.

~~66. The method of claim 65,~~ wherein the granulocytes comprise neutrophils and/or eosinophils, optionally.

~~67. The method of claim 65 or 66, wherein the granulocytes comprise eosinophils.~~

~~68. The method of any one of claims 65 to 67,~~ wherein the total number of granulocytes is determined by immunohistochemical (IHC) analysis or bronco-alveolar lavage (BAL) fluid differential cell count, optionally wherein the granulocytes are in the alveoli and/or in the interstitial fluid; and/or.

~~69. The method of any one of claims 65 to 68, wherein the granulocytes are in the alveoli.~~

~~70. The method of any one of claims 65 to 68, wherein the granulocytes are in the interstitial fluid.~~

~~71. The method of any one of the preceding claims, wherein upon administration to a (c) the antibody is to be administered to a subject and~~, the antibody reduces the total number of mononuclear cells, optionally wherein the mononuclear cells comprise macrophages optionally M1 macrophages and/or wherein the mononuclear cells comprise lymphocytes and/or wherein the mononuclear cells comprise monocytes, optionally wherein the total number of mononuclear cells is determined by immunohistochemical (IHC) analysis or bronco-alveolar lavage (BAL) fluid differential cell count, optionally wherein the mononuclear cells are in the alveoli or in the interstitial fluid; and/or.

~~72. The method of claim 71, wherein the mononuclear cells comprise macrophages.~~

~~73. The method of claim 71 or 72, wherein the macrophages comprise M1 macrophages.~~

~~74. The method of any one of claims 71 to 73, wherein the mononuclear cells comprise lymphocytes.~~

~~75. The method of any one of claims 71 to 74, wherein the mononuclear cells comprise monocytes.~~

~~76. The methods of any one of claims 71 to 74, wherein the total number of mononuclear cells is determined by immunohistochemical (IHC) analysis or broncho alveolar lavage (BAL) fluid differential cell count.~~

~~77. The method of any one of claims 71 to 76, wherein the mononuclear cells are in the alveoli.~~

~~78. The method of any one of claims 71 to 76, wherein the mononuclear cells are in the interstitial fluid.~~

~~79. The method of any one of the preceding claims, wherein upon administration (d) the antibody is to be administered to a subject, and the subject maintains or increases body weight relative to baseline levels; and/or~~

~~80. The method of any one of the preceding claims, wherein upon administration (e) the antibody is to be administered to a subject, and the antibody maintains or increases body weight relative to a different anti-inflammatory therapeutic; and/or~~

~~81. The method of any of the preceding claims, wherein upon administration (f) the antibody is to be administered to a subject and, the antibody reduces the spleen size or reverses spleen enlargement relative to baseline levels, and/or wherein the antibody reduces the spleen size or reverses splenomegaly relative to a different anti-inflammatory therapeutic, optionally wherein the spleen size or splenomegaly is determined using palpation, percussion, ultrasound, computerized tomography (CT) scan or magnetic resonance imaging (MRI); and/or~~

~~82. The method of any of the preceding claims, wherein upon administration to a subject, the antibody reduces the spleen size or reverses splenomegaly relative to a different anti-inflammatory therapeutic.~~

~~83. The method of claim 81 or 82, wherein the spleen size or splenomegaly is determined using palpation, percussion, ultrasound, computerized tomography (CT) scan or magnetic resonance imaging (MRI).~~

- ~~84. The method of any one of claims 1 and 13-83, wherein the (g) the inflammatory disease is acute lung injury or acute respiratory distress syndrome (ARDS); and/or-~~
- ~~85. The method of any one of claims 1 and 13-83, wherein the inflammatory disease is acute respiratory distress syndrome (ARDS)-~~
- ~~86. The method of any one of the preceding claims, wherein upon administration (h) the antibody is to be administered to a subject, and the antibody increases net alveolar fluid clearance relative to baseline levels or relative to a different anti-inflammatory therapeutic, optionally wherein net alveolar fluid clearance is determined by measuring sequential edema fluid protein concentrations, optionally wherein the sequential edema fluid protein concentrations are measured with ELISA; and/or-~~
- ~~87. The method of any one of the preceding claims, wherein upon administration to a subject, the antibody increases net alveolar fluid clearance relative to a different anti-inflammatory therapeutic-~~
- ~~88. The method of claim 86 or 87, wherein net alveolar fluid clearance is determined by measuring sequential edema fluid protein concentrations-~~
- ~~89. The method of claim 88, wherein the sequential edema fluid protein concentrations are measured with ELISA-~~
- ~~90. The method of any one of claims 1 and 13-83, wherein (i) the inflammatory disease is SARS-Cov-2,-~~
- ~~91. The method of claim 90, and wherein the antibody is to be administered upon administration to a subject, and the subject maintains or increases body weight relative to baseline levels, optionally wherein the antibody maintains or increases body weight relative to a different anti-inflammatory therapeutic; and/or-~~
- ~~92. The method of claim 90 or 91, wherein upon administration to a subject, the antibody maintains or increases body weight relative to a different anti-inflammatory therapeutic-~~
- ~~93. The method of any one of the preceding claims, wherein upon administration (j) the antibody is to be administered to a subject, and the antibody reduces the concentration of inflammatory cytokines and chemokines relative to baseline levels and/or -~~
- ~~94. The method of any one of the preceding claims, wherein upon administration to a subject, the antibody reduces the concentration of inflammatory cytokines and chemokines~~

relative to a different anti-inflammatory therapeutic, optionally wherein the inflammatory cytokines and chemokines are in bronco-alveolar lavage (BAL) samples and/or in lung homogenate samples, optionally-

~~95. The method of claim 93 or 94, wherein the inflammatory cytokines and chemokines are in bronco-alveolar lavage (BAL) samples-~~

~~96. — The method of any one of claims 93 to 95, wherein the inflammatory cytokines and chemokines are in lung homogenate samples-~~

~~97. — The method of any one of claims 93 to 96,~~ wherein the inflammatory cytokines and chemokines comprise one or more of: IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN γ , GM-CSF, TNF α , CCL2, CCL3, CCL4, CCL5, CCL19, CCL20, CCL25, CXCL1, CXCL2, and CXCL10, or-

~~98. — The method of any one of claims 93 to 96,~~ wherein the inflammatory cytokines and chemokines comprise VEGF, or -

~~99. — The method of any one of claims 93 to 96,~~ wherein the inflammatory cytokines and chemokines comprise one or more of: GMCSF, VEGF, IL17F, IL-1 beta, IL-6, IFN γ , IL-8, and KC, optionally-

~~100. — The method of any one of claims 93 to 98,~~ wherein the inflammatory cytokines and chemokines are measured using ELISA or -

~~101. The method of any one of claims 93 to 98, wherein the inflammatory cytokines and chemokines are measured~~ using Luminex Multiplex Assay.

~~102.13.~~ The ~~method-use~~ of any one of claims 1 ~~and 13-83~~ to 12(f), wherein:

-the inflammatory disease is a viral infection, optionally wherein

the antibody is to be administered to a subject and the antibody increases anti-inflammatory cytokines and chemokines relative to baseline levels; and/or

the antibody is to be administered to a subject and the antibody increases anti-inflammatory cytokines and chemokines relative to a different anti-inflammatory therapeutic; and/or

the anti-inflammatory cytokines and chemokines comprise one or more of: IL-10 and IL27p28; and/or

the anti-inflammatory cytokines and chemokines are in bronco-alveolar lavage (BAL) samples; and/or

the inflammatory cytokines and chemokines are measured using multiplex electrochemiluminescence MSD assay or using Luminex Multiplex Assay;

or

the inflammatory disease is RSV.

~~103.—The method of claim 102, wherein upon administration to a subject, the antibody increases anti-inflammatory cytokines and chemokines relative to baseline levels.~~

~~104.—The method of claim 102 or 103, wherein upon administration to a subject, the antibody increases anti-inflammatory cytokines and chemokines relative to a different anti-inflammatory therapeutic.~~

~~105.—The method of any one of claims 102-104, wherein the anti-inflammatory cytokines and chemokines comprise one or more of: IL-10 and IL-27p28.~~

~~106.—The method of any one of claims 102-105, wherein the anti-inflammatory cytokines and chemokines are in bronco-alveolar lavage (BAL) samples.~~

~~107.—The method of any one of claims 102-106, wherein the inflammatory cytokines and chemokines are measured using multiplex electrochemiluminescence MSD assay.~~

~~108.—The method of any one of claims 102-106, wherein the inflammatory cytokines and chemokines are measured using Luminex Multiplex Assay.~~

~~109._____T
he method of any one of claims 1 to 83 and 86 to 101, wherein the inflammatory disease is RSV.~~

~~110.—The method of any one of the preceding claims use of any one of claims 1 to 13, wherein upon administration wherein the antibody is to be administered to a subject, and the antibody reduces fibrosis in the lungs relative to baseline levels, and/or~~

~~111.14._____The method of any one of the preceding claims, wherein upon administration to a subject, the antibody reduces fibrosis in the lungs relative to a different anti-inflammatory therapeutic, optionally wherein the fibrosis is determined by IHC analysis or by Quantitative High Resolution Computed Tomography (qHRCT).~~

~~112.~~ The method of claim 110 or 111, wherein the fibrosis is determined by IHC analysis.

~~113.~~ The method of claim 110 or 111, wherein the fibrosis is determined by Quantitative High Resolution Computed Tomography (qHRCT).

~~114-15.~~ The ~~method use~~ of any one of claims 1 ~~and 13-83~~ to 12(f), wherein:

the inflammatory disease is arthritis, optionally wherein the antibody is to be administered to a subject and the antibody reduces the concentration of inflammatory cytokines and chemokines relative to baseline levels and/or relative to a different anti-inflammatory therapeutic, optionally wherein the inflammatory cytokines and chemokines comprise one or more of: IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN γ , GM-CSF, TNF α , CCL2, CCL3, CCL4, CCL5 CCL19, CCL20, CCL25, CXCL1, CXCL2, and CXCL10;

or-

~~115.~~ The method of 114, wherein upon administration to a subject, the antibody ~~reduces the concentration of inflammatory cytokines and chemokines relative to baseline levels.~~

~~116.~~ The method of 114 or 115, wherein upon administration to a subject, the antibody ~~reduces the concentration of inflammatory cytokines and chemokines relative to a different anti-inflammatory therapeutic.~~

~~117.~~ The method of claim 115 or 116, wherein the inflammatory cytokines and chemokines comprise one or more of: IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN γ , GM-CSF, TNF α , CCL2, CCL3, CCL4, CCL5 CCL19, CCL20, CCL25, CXCL1, CXCL2, and CXCL10.

~~118.~~ The method of any one of claims 1 and 13-83, wherein the inflammatory disease is colitis or-

~~119.~~ The method of any one of claims 1 and 13-83, wherein the inflammatory disease is inflammatory bowel disease, optionally wherein the antibody is to be administered to a subject and the antibody results in a normal stool consistency or hardens the subject's stool consistency relative to baseline levels and/or relative to a different anti-inflammatory therapeutic optionally wherein the stool consistency is determined using the Bristol Stool Scale; and/or wherein the antibody is to be administered to a subject and the antibody reduces

blood or results in the absence of blood in the subject's stool relative to baseline levels or relative to a different anti-inflammatory therapeutic, optionally wherein the blood in the subject's stool is measured using a hemocult test; and/or wherein the antibody is to be administered to a subject and the antibody reduces the concentration of inflammatory cytokines and chemokines relative to baseline levels or relative to a different anti-inflammatory therapeutic, optionally wherein the inflammatory cytokines and chemokines comprise one or more of: IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN γ , GM-CSF, TNF α , CCL2, CCL3, CCL4, CCL5, CCL19, CCL20, CCL25, CXCL1, CXCL2, and CXCL10;

~~120. The method of claim 118 or 119, wherein upon administration to a subject, the antibody results in a normal stool consistency or hardens the subject's stool consistency relative to baseline levels.~~

~~121. The method of any one of claims 118 to 120, wherein upon administration to a subject, the antibody results in a normal stool consistency or hardens the subject's stool consistency relative to a different anti-inflammatory therapeutic.~~

~~122. The method of claim 120 or 121, wherein the stool consistency is determined using the Bristol Stool Scale.~~

~~123. The method of any one of claims 118 to 122, wherein upon administration to a subject, the antibody reduces blood or results in the absence of blood in the subject's stool relative to baseline levels.~~

~~124. The method of any one of claims 118 to 123, wherein upon administration to a subject, the antibody reduces blood or results in the absence of blood in the subject's stool relative to a different anti-inflammatory therapeutic.~~

~~125. The method of claim 123 or 124, wherein the blood in the subject's stool is measured using a hemocult test.~~

~~126. The method of any one of claims 118 to 125, wherein upon administration to a subject, the antibody reduces the concentration of inflammatory cytokines and chemokines relative to baseline levels.~~

~~127. The method of 118 or 126, wherein upon administration to a subject, the antibody reduces the concentration of inflammatory cytokines and chemokines relative to a different anti-inflammatory therapeutic.~~

~~128. The method of claim 126 or 127, wherein the inflammatory cytokines and chemokines comprise one or more of: IL-1 α , IL-1 β , IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN γ , GM-CSF, TNF α , CCL2, CCL3, CCL4, CCL5, CCL19, CCL20, CCL25, CXCL1, CXCL2, and CXCL10.~~

~~129. The method of any one of claims 1 and 13-83, wherein _____ or~~

the inflammatory disease is myocardial infarction, optionally wherein the antibody reduces infarct size relative to baseline levels and/or relative to a different anti-inflammatory therapeutic and/or wherein the antibody is to be administered to a subject and the antibody increases left ventricular ejection fraction relative to baseline levels and/or relative to a different anti-inflammatory therapeutic, and/or wherein the antibody is to be administered to a subject and the antibody decreases left ventricular end diastolic volume relative to baseline levels or relative to a different anti-inflammatory therapeutic, and/or wherein the antibody is to be administered to a subject and the antibody decreases inflammatory cell recruitment in the infarcted myocardium relative to baseline levels or relative to a different anti-inflammatory therapeutic, optionally wherein the inflammatory cells are selected from CD45⁺, CD11b⁺, Ly6C^{hi}, CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺, CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺/Ly6C^{hi}, and CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺/Ly6C^{lo}, optionally wherein the inflammatory cell recruitment is measured using flow cytometry.

~~130. The method of claim 129, wherein upon administration to a subject, the antibody reduces infarct size relative to baseline levels.~~

~~131. The method of claim 129 or 130, wherein upon administration to a subject, the antibody reduces infarct size relative to a different anti-inflammatory therapeutic.~~

~~132. The method of claim 129-131, wherein upon administration to a subject, the antibody increases left ventricular ejection fraction relative to baseline levels.~~

~~133. The method of claim 129-132, wherein upon administration to a subject, the antibody increases left ventricular ejection fraction relative to a different anti-inflammatory therapeutic.~~

~~134. The method of claim 129-133, wherein upon administration to a subject, the antibody decreases left ventricular end diastolic volume relative to baseline levels.~~

~~135. The method of claim 129-134, wherein upon administration to a subject, the antibody decreases left ventricular end diastolic volume relative to a different anti-inflammatory therapeutic.~~

~~136. The method of claim 129-135, wherein upon administration to a subject, the antibody decreases inflammatory cell recruitment in the infarcted myocardium relative to baseline levels.~~

~~137. The method of claim 129-136, wherein upon administration to a subject, the antibody decreases inflammatory cell recruitment in the infarcted myocardium relative to a different anti-inflammatory therapeutic.~~

~~138. The method of claim 136 or 137, wherein the inflammatory cells are selected from CD45⁺, CD11b⁺, Ly6C^{hi}, CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺, CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺/Ly6C^{hi}, and CD45⁺/CD90.2⁻/NK1.1⁻/CD11b⁺/Ly6C^{lo}.~~

~~139. The method of any one of claims 136-138, wherein the inflammatory cell recruitment is measured using flow cytometry.~~

140-16. The ~~method of any one of the preceding claims~~use of any one of claims 1 to 15, wherein:

~~upon administration the antibody is to be administered to a subject, and the antibody results in a reduced need for systemic steroids; and/or-~~

~~141. The method of any one of the preceding claims, wherein the different anti-inflammatory therapeutic comprises one or more of: a non-steroidal anti-inflammatory drug (NSAID), a steroidal anti-inflammatory drug, a beta-agonist, an anticholinergic agent, an antihistamine, and a methyl xanthine; and/or-~~

~~142. The method of any one of the preceding claims, wherein the different anti-inflammatory therapeutic comprises any one of: an IL-6 inhibitor, anti-GM-CSF, anti-TNF α , anti-IL-1 α , dexamethasone, a chemokine and chemokine receptor antagonist, and a JAK inhibitor.~~

143-17. The ~~method-use~~ of any one of ~~the preceding claims~~claims 1 to 16, wherein the antibody is to be administered biweekly or weekly.

~~144.—The method of any one of the preceding claims, wherein the antibody is administered weekly.~~